Bayer submits cancer drug for market authorisation in Japan

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Source: http://www.reuters.com/article/2012/12/21/bayer-japan-idUSWEA885820121221?feedType=RSS&feedName=rbssHealthcareNews&rpc=43

Turkey Cooking Time red dawn sweet potato pie sweet potato pie green bean casserole recipe Kmart Black Friday PlanetSide 2